Clinical Trial: Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional




Official Title: Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Brief Summary: This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain cells.